Analysts Expect Antares Pharma Inc (ATRS) Will Post Quarterly Sales of $15.13 Million

Wall Street analysts expect Antares Pharma Inc (NASDAQ:ATRS) to announce sales of $15.13 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Antares Pharma’s earnings, with the lowest sales estimate coming in at $13.30 million and the highest estimate coming in at $17.43 million. Antares Pharma reported sales of $15.05 million in the same quarter last year, which indicates a positive year-over-year growth rate of 0.5%. The firm is scheduled to announce its next earnings results on Tuesday, November 6th.

On average, analysts expect that Antares Pharma will report full year sales of $59.66 million for the current fiscal year, with estimates ranging from $55.20 million to $63.18 million. For the next financial year, analysts anticipate that the company will post sales of $105.40 million per share, with estimates ranging from $80.40 million to $137.82 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.01). Antares Pharma had a negative return on equity of 64.96% and a negative net margin of 35.53%. The company had revenue of $14.16 million during the quarter, compared to analysts’ expectations of $13.70 million.



A number of brokerages have commented on ATRS. ValuEngine lowered Antares Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, August 2nd. Piper Jaffray Companies restated a “buy” rating and set a $4.00 price objective on shares of Antares Pharma in a research report on Friday, August 17th. HC Wainwright set a $5.00 price objective on Antares Pharma and gave the stock a “buy” rating in a research report on Friday, August 17th. Finally, BidaskClub upgraded Antares Pharma from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 8th.

In other news, Director Jacques Gonella sold 49,507 shares of Antares Pharma stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $3.09, for a total transaction of $152,976.63. Following the completion of the sale, the director now directly owns 9,985,848 shares in the company, valued at approximately $30,856,270.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Robert F. Apple sold 43,000 shares of Antares Pharma stock in a transaction dated Tuesday, August 21st. The shares were sold at an average price of $3.75, for a total value of $161,250.00. Following the sale, the chief executive officer now owns 1,573,562 shares of the company’s stock, valued at $5,900,857.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 343,000 shares of company stock valued at $1,088,250. 12.20% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the company. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Antares Pharma by 127.0% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 51,612 shares of the specialty pharmaceutical company’s stock valued at $133,000 after buying an additional 28,875 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Antares Pharma by 4.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 744,188 shares of the specialty pharmaceutical company’s stock worth $1,921,000 after purchasing an additional 32,626 shares during the last quarter. JW Asset Management LLC lifted its holdings in Antares Pharma by 2.8% in the 2nd quarter. JW Asset Management LLC now owns 1,820,524 shares of the specialty pharmaceutical company’s stock worth $4,697,000 after purchasing an additional 50,000 shares during the last quarter. MetLife Investment Advisors LLC lifted its holdings in Antares Pharma by 281.1% in the 1st quarter. MetLife Investment Advisors LLC now owns 71,731 shares of the specialty pharmaceutical company’s stock worth $158,000 after purchasing an additional 52,911 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Antares Pharma by 7.4% in the 2nd quarter. Northern Trust Corp now owns 1,718,251 shares of the specialty pharmaceutical company’s stock worth $4,433,000 after purchasing an additional 119,091 shares during the last quarter. Institutional investors and hedge funds own 38.93% of the company’s stock.

NASDAQ ATRS traded up $0.07 during trading on Monday, reaching $3.37. 18,708 shares of the company’s stock were exchanged, compared to its average volume of 1,097,791. Antares Pharma has a fifty-two week low of $1.58 and a fifty-two week high of $4.09. The firm has a market capitalization of $528.99 million, a PE ratio of -30.57 and a beta of 0.34. The company has a current ratio of 2.33, a quick ratio of 1.89 and a debt-to-equity ratio of 1.01.

About Antares Pharma

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Recommended Story: Are Wall Street analysts’ stock ratings worth following?

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply